[Neovir therapy in acute hepatitis C].
Neovir, an inductor of interferon-alpha, was injected intramuscularly to 15 male patients aged 16-44 years with diagnosed acute viral hepatitis in a dose of 250 mg a day, 2-3 times a week, for 3 months. By the end of the therapy hepatitis C virus RNA could still be isolated in 84.6% of the patients; the values of AlaT, AsaT and alkaline phosphatase exceeded the normal levels twofold. The result of the therapy is regarded as ineffective.
Maksimov
S L
SL
State Medical Stomatology University, State Clinical Infectious Hospital No. 2, Central Research Institute of Epidemiology, Moscow, Russia.
Iushchuk
N D
ND
Roslyĭ
I M
IM
Kravchenko
A V
AV
Danilova
T V
TV
D000166:Acridines / Q000627:therapeutic use*; D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D015415:Biomarkers / Q000097:blood; D004334:Drug Administration Schedule; D016174:Hepacivirus / Q000302:isolation & purification; D006526:Hepatitis C / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007273:Injections, Intramuscular; D007369:Interferon Inducers / Q000627:therapeutic use*; D008297:Male; D012367:RNA, Viral / Q000032:analysis; D016896:Treatment Outcome; D019562:Viral Load
D000166:Acridines; D015415:Biomarkers; D007369:Interferon Inducers; D012367:RNA, Viral; C077681:Camedon; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase